Albert Labs is developing KRN-101, a psilocybin-based therapy aimed at alleviating cancer-related anxiety, which affects over 15 million people globally. The company utilizes a patient-first approach and real-world evidence to expedite clinical trials and regulatory approval for its natural neurological treatments.

Atai Life Sciences is a clinical-stage biopharmaceutical company developing novel therapeutics for mental health conditions. They are advancing psychedelic and non-psychedelic compounds, including DMT, MDMA, and psilocin, to offer rapid-acting and durable relief for patients with treatment-resistant depression, social anxiety disorder, and cognitive impairment.

Bexson Biomedical is developing a subcutaneous delivery system for its BB106 non-opioid therapy, targeting acute pain management to provide an alternative to opioids. The company's formulation platform enhances the pharmacokinetics of existing drugs, enabling effective home health delivery and addressing the challenges of pain treatment without the risks associated with opioid use.

Cybin develops tryptamine-based psychedelic therapeutics using proprietary drug discovery platforms and controllable drug delivery systems to treat mental health conditions such as Major Depressive Disorder and Generalized Anxiety Disorder. The company aims to provide safe and effective treatment options that address the unmet needs of patients suffering from these disorders.

Gilgamesh Pharmaceuticals develops new chemical entities targeting the root causes of depression, anxiety, and stress-related disorders through advanced medicinal chemistry and an AI-powered discovery platform. Their therapies include rapid-acting, non-hallucinogenic neuroplastogens and safer ibogaine analogs, offering improved efficacy and safety profiles for patients.

This company provides evidence-based ketamine-assisted psychotherapy retreats for treating stress, burnout, and depression. Their personalized programs include medical assessment, online preparation with a psychotherapist, guided ketamine treatments in a tranquil setting, and post-retreat integration sessions. The service aims to offer safer access to life-changing mental health therapies through structured protocols.

Maya Health is a software platform that tracks and measures health outcomes through data analytics and visualization tools. It provides clients with actionable insights to improve their health management and decision-making processes.

Mindstate Design Labs operates a clinical-stage AI neuroengineering platform to develop novel therapeutics for mental health conditions. Their Osmanthus platform synthesizes psychoactive effect reports and biochemical data to map the biological basis of emotional and cognitive states. This technology drives the development of pharmaceutical compounds designed to precisely induce specific therapeutic states like empathy or awe.

Mycrodose Therapeutics develops advanced drug delivery systems that enhance the precision and efficacy of pharmaceutical treatments. The company addresses the challenge of inefficient drug administration by improving bioavailability and patient compliance through targeted delivery mechanisms.

Numinus offers psychedelic-assisted psychotherapy, utilizing methods such as Ketamine-Assisted Therapy and Transcranial Magnetic Stimulation (TMS) to provide effective treatment for mental health conditions that do not respond to traditional therapies. The company also provides accredited training for healthcare providers, enhancing the availability of evidence-based psychedelic therapy in clinical settings.

Ocean.io is a prospecting data platform that utilizes AI-powered Lookalike Search to help B2B sales and marketing teams identify highly specific accounts and contacts that match their ideal customer profiles. By providing precise and reliable data, the platform enables companies to efficiently build targeted prospect lists, improving lead conversion rates and reducing costs per marketing qualified lead.

WeSana Health develops psilocybin-based therapies aimed at treating mental health disorders such as depression and anxiety. The company focuses on advancing clinical applications of psilocybin to improve patient outcomes and enhance therapeutic efficacy.